Recently, Pfizer made public a $525 million acquisition of ReViral’s novel therapy for respiratory syncytial virus (RSV). Subsequently, there has been an increased interest in developing RSV therapies ...

A research team led by a Duke professor recently developed a novel computational model to predict antibody structures, a significant breakthrough for disease prevention efforts. A study published in ...

Bispecific antibodies (bispecifics) can simultaneously target two distinct antigens or epitopes, offering novel therapeutic strategies such as enhancing immune cell targeting of cancer cells or ...

Ivelin Georgiev, PhD, professor of Pathology, Microbiology and Immunology, director of the Vanderbilt Center for Computational Microbiology and Immunology, and the project principal investigator. An ...

Human respiratory syncytial virus (RSV) remains a significant public health concern, particularly for vulnerable populations such as infants, young children, and immunocompromised individuals. In this ...

CD40-targeting therapies have been proposed as an interesting alternative to overcome resistance to immune checkpoint inhibitors. In particular, bispecific CD40 antibodies can target CD40 more ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group (KRX:068270) today announced the launch of two rapid kits for SARS-CoV-2 in the US by the third week of August. SAMPINUTE TM COVID-19 Antigen MIA ...

Anglo-American life science firm AMSBIO announces a new range of recombinant antigens and antibodies for Zika virus, which are suited for the development of rapid assays and to overcome the problem of ...

The World Health Organization (WHO) has announced its recommendations for the 2026-2027 Northern Hemisphere influenza vaccine ...

People with diabetes have been urged to take extra caution during the COVID-19 pandemic. If you have diabetes, you’ve likely heard that COVID-19 is generally considered to be more dangerous for people ...